Efficacy of PD-(L)1 inhibitors plus anlotinib in the second-line treatment of extensive-stage small cell lung cancer

Efficacy of PD-(L)1 inhibitors plus anlotinib in the second-line treatment of extensive-stage small cell lung cancer

Abstract Background The efficacy of second-line therapy for extensive-stage small cell lung cancer (ES-SCLC) is still limited, with the PFS of 2–3 months. Given the synergistic effect of PD-(L)1 inhibitors and anti-angiogenic agents, their combination represents a novel and promising strategy to rep...

Full description

Saved in:
Bibliographic Details
Main Authors: Jian Zhang, Zijie Wu, Shuyun Wang, Yanxin Sun, Jiake Wu, Dahai Wang, Yihui Ge, Juan Li, Haifeng Sun, Qinglei Cheng, Aiqin Gao, Yuping Sun
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Cancer
Subjects:
Extensive-stage small cell lung cancer (ES-SCLC)
PD-(L)1 inhibitors
Anlotinib
Efficacy
Safety
Online Access:https://doi.org/10.1186/s12885-025-14458-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-14458-5

Similar Items